COST

943.02

-1.17%↓

KO

69.01

+0.1%↑

PM

163.8

+0.56%↑

PEP

139.45

-0.06%↓

KDP.US

33.33

+0.03%↑

COST

943.02

-1.17%↓

KO

69.01

+0.1%↑

PM

163.8

+0.56%↑

PEP

139.45

-0.06%↓

KDP.US

33.33

+0.03%↑

COST

943.02

-1.17%↓

KO

69.01

+0.1%↑

PM

163.8

+0.56%↑

PEP

139.45

-0.06%↓

KDP.US

33.33

+0.03%↑

COST

943.02

-1.17%↓

KO

69.01

+0.1%↑

PM

163.8

+0.56%↑

PEP

139.45

-0.06%↓

KDP.US

33.33

+0.03%↑

COST

943.02

-1.17%↓

KO

69.01

+0.1%↑

PM

163.8

+0.56%↑

PEP

139.45

-0.06%↓

KDP.US

33.33

+0.03%↑

Search

Udemy Inc

Slēgts

SektorsPatēriņa aizsardzības

7.3 -1.22

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.19

Max

7.49

Galvenie mērījumi

By Trading Economics

Ienākumi

8.1M

-1.8M

Pārdošana

358K

200M

Peļņas marža

-0.884

Darbinieki

1,246

EBITDA

7.1M

-4.5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+32.05% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 28. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

67M

1.1B

Iepriekšējā atvēršanas cena

8.52

Iepriekšējā slēgšanas cena

7.3

Ziņu noskaņojums

By Acuity

50%

50%

70 / 150 Rangs Consumer defensive

Udemy Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. aug. 21:42 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Cabot to Acquire Mexico Carbon Manufacturing From Bridgestone

2025. g. 4. aug. 21:21 UTC

Peļņas
Galvenie tirgus virzītāji

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025. g. 4. aug. 20:45 UTC

Peļņas

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025. g. 4. aug. 19:15 UTC

Galvenie tirgus virzītāji

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

2025. g. 4. aug. 23:41 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. aug. 23:41 UTC

Tirgus saruna

Nikkei May Rise on Fed Stimulus Hopes

2025. g. 4. aug. 23:28 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 4. aug. 23:28 UTC

Tirgus saruna

Gold Seen Stuck in Range as Investors Await Fed's Next Move -- Market Talk

2025. g. 4. aug. 21:30 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025. g. 4. aug. 21:21 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Berkshire Stock Was Hammered Monday. It's Like 1999 Again. -- Barrons.com

2025. g. 4. aug. 21:18 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Expectations. -- Barrons.com

2025. g. 4. aug. 20:25 UTC

Tirgus saruna

India Hits Back Over Russian Oil Purchases -- Market Talk

2025. g. 4. aug. 20:25 UTC

Peļņas

Transocean 2Q Loss $938M >RIG

2025. g. 4. aug. 20:25 UTC

Peļņas

Transocean 2Q Loss/Shr $1.06 >RIG

2025. g. 4. aug. 20:18 UTC

Peļņas

Palantir Stock Jumps. Earnings Blew Past Wall Street's Stratospheric Expectations. -- Barrons.com

2025. g. 4. aug. 20:15 UTC

Peļņas

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025. g. 4. aug. 20:14 UTC

Peļņas

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025. g. 4. aug. 20:13 UTC

Peļņas

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025. g. 4. aug. 20:09 UTC

Peļņas

Viper Energy: Initiating Avg Daily Production Guidance for 3Q of 46,000 to 49,000 Bo/d (86,000 to 92,000 Boe/d) >VNOM

2025. g. 4. aug. 20:06 UTC

Peļņas

Palantir Earnings Blow Past Wall Street's Stratospheric Expectations -- Barrons.com

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025. g. 4. aug. 20:01 UTC

Peļņas

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025. g. 4. aug. 19:41 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower -- Market Talk

2025. g. 4. aug. 19:28 UTC

Tirgus saruna

U.S. Hiring Expected to Recover Once Uncertainty Dissipates -- Market Talk

2025. g. 4. aug. 19:07 UTC

Tirgus saruna

Oil Extends Losing Streak As OPEC+ to Raise Output -- Market Talk

2025. g. 4. aug. 18:27 UTC

Tirgus saruna

Gold Climbs on Rate Cut Speculation -- Market Talk

Salīdzinājums

Cenas izmaiņa

Udemy Inc Prognoze

Cenas mērķis

By TipRanks

32.05% augšup

Prognoze 12 mēnešiem

Vidējais 9.6 USD  32.05%

Augstākais 11 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Udemy Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

4

Pirkt

4

Turēt

0

Pārdot

Noskaņojums

By Acuity

70 / 150 Rangs Patēriņa aizsardzības

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Udemy Inc

Udemy, Inc., a learning company, that operates a marketplace platform for learning skills in the United States and internationally. The company offers skill acquisition, development, and validation courses for organizations and individuals, through direct-to-consumer or Udemy Business offerings in various languages. Its courses provide learning objectives, such as reskilling or upskilling in technology, business, soft skills, and personal development, as well as learners receive access to interactive learning tools comprising quizzes, exercises, and instructor questions-and-answers. The company was incorporated in 2010 and is headquartered in San Francisco, California.